Researchers are using artificial intelligence to dramatically speed up the discovery of treatments for motor neurone disease (MND) and other neurological conditions. The breakthrough approach combines machine learning with lab-grown brain cells to identify promising drugs far faster than traditional methods.

AI Meets Neuroscience

At the Institute of Neurology, clinicians are gathering iris scans, voice recordings, and leveraging AI to analyze massive datasets to spot early indicators of neurological disease progression. This multimodal data collection enables AI algorithms to detect subtle patterns invisible to human observers.

Testing on Artificial Brain Cells

The most innovative aspect involves cultivating stem cells into populations of neurons—brain cells grown in the laboratory. Robots and specialized algorithms then test existing approved drugs on thousands of batches of these artificial brain cells simultaneously.

Machine learning models trained to recognize disease signatures work to identify which drugs could convert the neurological disease state back to a healthy one.

Repurposing Over Inventing

The beauty of this approach lies in efficiency: instead of developing entirely new drugs—a process that can take over 10 years—researchers test existing, already-approved pharmaceuticals for new applications. This dramatically shortens the path from discovery to clinical trials.

A Tipping Point

Researchers believe they're at an inflection point in neurological medicine. The combination of high-throughput AI analysis, stem cell biology, and computational drug modeling creates unprecedented opportunities for rapid therapeutic discovery.

Similar work at MIT has used AI to identify novel antibiotic compounds for superbugs, while Harvard's TxGNN neural network surfaces existing drugs for rare disease treatment—demonstrating that AI-driven drug repurposing works across multiple disease categories.

Source: BBC News